Breaking News

Financial Report: Alkermes

May 23, 2013

Revenues up 25% in the quarter

Alkermes

4Q Revenues: $163.4 million (+25%)

4Q Earnings: $3.0 million (loss of $63.4 million 4Q12)

FY Revenues: $575.5 million (+48%)

FY Earnings: $25.0 million (loss of $113.7 million FY12)

Comments: Revenues from the company’s five key commercial products for the quarter grew 26% to $89.5 million. Results reflect the completion of the merger of Alkermes with Elan Drug Technologies (EDT) in Sept. 2011. For the year, revenues included $50.0 million of intellectual property license revenue unrelated to key development programs.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision